Sharekhan

Bliss GVS Pharma Ltd

Fri 22/05/2026,15:58:59 | NSE : BLISSGVS

₹ 300.355.15 (1.74%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 295.00

Previous Close

₹ 295.20

Volume

2320688

Mkt Cap ( Rs. Cr)

₹3177.37

High

₹ 304.00

Low

₹ 292.70

52 Week High

₹ 304.00

52 Week Low

₹ 118.00

Book Value Per Share

₹ 109.38

Dividend Yield

0.49

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Bliss GVS Pharma Ltd

Your Vote -

Buy

84.38%

Hold

9.38%

Sell

6.25%

84.38%

32 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

300.35

7411

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

7411

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Bliss GVS Pharma Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Bliss GVS Pharma - Disclosure under Regulation 30A of LODR

    23 May 2026, 11:07PM Please find herewith the disclosures under Regulations 30 and Regulations 30A of the SEBI LODR - Public Announcement for Execution of Share Purchase A
  • Bliss GVS Pharma - Board Meeting Outcome for Outcome Of Board Meeting Held On May 23, 2026

    23 May 2026, 11:01PM Please find herewith the outcome of Board Meeting held on May 23, 2026
  • Bliss GVS Pharma - Public Announcement In Relation To Open Offer To Public Shareholders (As Defined Under Public Announcement

    23 May 2026, 10:38PM Please find herewith the Public Announcement in relation to Open Offer to public shareholders issued by SBI Capital Markets Limited.
  • Bliss GVS Pharma - Copy of Newspaper Publication

    14 May 2026, 5:58PM Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication
  • Bliss GVS Pharma - Outcome of Board Meeting

    12 May 2026, 11:08PM Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
  • Bliss GVS Pharma - Announcement under Regulation 30 (LODR)-Change in Management

    12 May 2026, 11:00PM Please find enclosed herewith the re-appointment of Internal Auditor of the Company for the financial year 2026-2027
  • Bliss GVS Pharma - Change in Management

    12 May 2026, 10:58PM Bliss GVS Pharma Limited has informed the Exchange about change in Management
  • Bliss GVS Pharma - General Updates

    12 May 2026, 10:56PM Bliss GVS Pharma Limited has informed the Exchange that the Board has approved the Final Dividend for the FY 2025-2026.
  • Bliss GVS Pharma - Corporate Action-Board approves Dividend

    12 May 2026, 10:51PM Recommended Final Dividend for the financial year ended March 31, 2026, subject to approval of the shareholders in the forthcoming 41st Annual General
  • Bliss GVS Pharma - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019\r\n

    12 May 2026, 10:45PM Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on May 12, 2026, the members has granted 1,
  • Bliss GVS Pharma - General Updates

    12 May 2026, 10:43PM Bliss GVS Pharma Limited has informed the Exchange about Grant of Options under Bliss GVS Pharma Limited Employee Stock Options Plan 2019
  • Bliss GVS Pharma Q4 net profit zooms 183.14% at Rs 32.42 cr

    12 May 2026, 10:40PM The company reported standalone net profit of Rs 32.42 crore for the quarter ended March 31, 2026 as compared to Rs 11.45 crore in the same period las
  • Bliss GVS Pharma - Audited Standalone & Consolidated Financial Results For The Quarter And Year Ended March 31, 2026

    12 May 2026, 10:32PM Please find attached herewith the audited standalone & consolidated financial results for the quarter and year ended March 31, 2026
  • Bliss GVS Pharma - Outcome of Board Meeting

    12 May 2026, 10:23PM Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
  • Bliss GVS Pharma - Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, May 12, 2026

    12 May 2026, 10:18PM We would like to inform you that the Board Meeting of the Company was held today i.e. on Tuesday, May 12, 2026, at the registered office of the Compan
  • Bliss GVS Pharma - Shareholders meeting

    12 May 2026, 8:10PM Bliss GVS Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regard
  • Bliss GVS Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    12 May 2026, 7:48PM Please find enclosed herewith the Scrutinizer's Report of Postal Ballot alongwith Voting Results.
  • Bliss GVS Pharma - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    12 May 2026, 7:45PM Please find enclosed herewith the Disclosure of Voting Results of the Postal Ballot along with Scrutinizer Report.
  • Bliss GVS Pharma - Board Meeting Intimation for Approval Of Audited (Standalone & Consolidated) Financial Results Of The Comp

    5 May 2026, 6:20PM Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and
  • Bliss GVS Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    17 Apr 2026, 4:50PM As of March 2026, 35.36% is owned by Indian Promoters and 64.64% by Public. <p align=justify> Institutional holds 15.49% (Insurance Companies 4.33%) a
  • Bliss GVS Pharma - Copy of Newspaper Publication

    10 Apr 2026, 4:07PM Bliss GVS Pharma Limited has informed the Exchange about Copy of the newspaper publication regarding the dispatch of the Postal Ballot Notice and E-vo
  • Bliss GVS Pharma - Shareholders meeting

    9 Apr 2026, 5:17PM Bliss GVS Pharma Limited has informed the Exchange regarding Notice of Postal Ballot regrading appointment of Independent Directors of the Company.
  • Bliss GVS Pharma - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    9 Apr 2026, 5:22PM Please find enclosed herewith the Postal Ballot Notice regarding the appointment of an Independent Director of the Company.
  • Bliss GVS Pharma - Credit Rating- New

    8 Apr 2026, 4:11PM Bliss GVS Pharma Limited has informed the Exchange about Credit Rating- New rating received from ICRA Limited
  • Bliss GVS Pharma - Announcement under Regulation 30 (LODR)-Credit Rating

    8 Apr 2026, 4:20PM Please find enclosed herewith the Intimation regarding the Credit Rating received by the Company from Investment Information and Credit Rating Agency
  • Bliss GVS Pharma - Copy of Newspaper Publication

    6 Apr 2026, 5:22PM Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication
  • Bliss GVS Pharma - Announcement under Regulation 30 (LODR)-Change in Directorate

    3 Apr 2026, 6:58PM We would like to inform you that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has
  • Bliss GVS Pharma - Outcome Of The Circular Resolution Passed By The Board Of Directors

    3 Apr 2026, 6:55PM We would like to inform you that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has
  • Bliss GVS Pharma - Appointment

    3 Apr 2026, 6:42PM Bliss GVS Pharma Limited has informed the Exchange regarding Appointment of Mr Mr. Vijayanarayanan Mahadevan as Non- Executive Independent Director o
  • Bliss GVS Pharma - Outcome of Board Meeting

    3 Apr 2026, 6:38PM We would like to inform you that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has
  • Bliss GVS Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    2 Apr 2026, 6:40PM Bliss GVS Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Bliss GVS Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    2 Apr 2026, 6:33PM Please find enclosed herewith the Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended March 31, 2026.
  • Bliss GVS approves to increase FII investment limit

    26 Feb 2019 , 10:09AM Board approves to increase the FPI/FII investment limit in the company
  • Bliss GVS board to consider disinvestment; stk up

    5 Jan 2018 , 12:01PM Bliss GVS board to meet on Jan 11, for considering disinvestment of subsidiary business

Key fundamentals

Evaluate the intrinsic value of Bliss GVS Pharma Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 1155.1882 1109.642 1054.0754 1014.0767 937.0434
Liabilities 1155.1882 1109.642 1054.0754 1014.0767 937.0434
Equity 10.5789 10.537 10.4691 10.4153 10.3678
Gross Profit 134.0345 91.5856 107.1687 90.1552 109.199
Net Profit 96.8744 68.9687 50.6449 85.4786 92.664
Cash From Operating Activities 123.1565 97.2054 125.9225 43.8057 114.0494
NPM(%) 13.27 10.33 8.36 14.28 14.56
Revenue 729.8076 667.2046 605.4597 598.3395 636.3567
Expenses 595.7731 575.619 498.291 508.1843 527.1577
ROE(%) 8.37 5.96 4.37 7.38 8

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
1 100 0.5 273.8
18 Feb 2026 0.5 50 0.5 208.07
24 Jul 2025 0.5 50 0.5 118.77
18 Jul 2024 0.5 50 0.5 119.05
12 Jul 2023 0.5 50 0.5 83.8
20 Jun 2022 0.5 50 0.5 79
13 Sep 2021 0.5 50 0.5 128.1
17 Sep 2020 0.5 50 0.5 102.35
1 100 0.5 173.6
14 Aug 2018 1 100 0.5 196.65
18 Sep 2017 0.6 60 0.5 177.2
0.5 50 0.5 95.2
08 Sep 2015 0.5 50 0.5 122.45
24 Feb 2015 0.2 20 0.5 110.9
13 Aug 2014 0.5 50 0.5 43.8
01 Aug 2013 0.4 40 0.5 28.6
25 Feb 2013 0.3 30 0.5 36.5
02 Aug 2012 0.4 40 0.5 23
24 Nov 2011 0.35 35 0.5 23.7
14 Jul 2011 0.3 30 0.5 22.5
25 Nov 2010 0.3 30 0.5 44.75

Peers

Other companies within the same industry or sector that are comparable to Bliss GVS Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 705.80 -0.07 0.00 171.33 -26.19 0.71
Lotus Eye Hospital and Institute Ltd 109.19 1.26 352.23 624.30 3.55 0.00
Vaishali Pharma Ltd 7.00 0.14 0.00 3916.47 3.13 0.00
Astec Lifesciences Ltd 771.80 4.77 0.00 588.73 -363.15 0.00

Company Info

1984 - Bliss GVS Pharma Limited was incorporated on 11th December, as public limited company and promoted by Mr Gautam Ashra. The company operates in two segments, health care products and pharma products. 2004 - Public shareholders of the company received an open offer by the Fedex Securities Ltd on behalf of Shri M G Wagle, Shri Gautam R Ashra & Shri Shibroor N Kamath. 2005 - Board of directors of the company had recommended the issue of bonus shares of 2 shares for every 5 shares. 2006 -Board of directors of the company on 9th May, 2006, had approved to takeover GVS Lab and to change the name of the company from 'Bliss Chemicals & Pharmaceuticals India Ltd' to 'Bliss GVS Pharma Ltd'. - Gautam Ashra, promoter director of the company, on 18th December 2006, sold 104,200 equity shares of the company for average sale price of Rs. 52.02 at the exchange. -Company has changed its name from Bliss Chemicals & Pharmaceuticals India Ltd. to Bliss GVS Pharma Ltd. 2007 - The board of the company had approved on 15th Jan 2007, to take over GVS Labs of S N Kamath for a consideration of Rs 160 million. The entire consideration will be paid by way of issue of 2,666,667 shares on a preferential basis to Kamath at a price of Rs 60 each (at a premium of Rs. 50 each). The takeover of GVS Lab was effective from Apr. 01, 2006. - The company had received an order of Rs. 25.00 crores for supply of Anti malarial Drugs for African Countries on November 2007. - The company set up its new manufacturing unit for tablets, dry syrup, oral suspension and suppository pessaries in the existing manufacturing facility at Palghar in Maharashtra. 2008 - Members at the extra ordinary general meeting of the company had approved split of shares of face Value of Rs 10 each into face value of Rs 1 each. -The company had fixed 18th March 2008 as the record date for the split of the equity shares of the company. The equity shares of face value Rs. 10 each will be sub divided in to face value of Rs. 1 each. -The Company has issued Bonus Shares in the Ratio of 3:5. 2009 -Company has received an Award from Pharmexcil -Company successfully completed its 25th year of operations. 2010 -Company has signed a Joint Venture Agreement with Kuwait -Mr. S N. Kamath, Promoter & Managing Director of the company has received a "National Award -2009 from Government of India in recognition outstanding performance Entrepreneurship under Medium Enterprises". -Registered Office of the Company has been shifted from 6/29-A, Udit Mittal Industry, Andheri Kurla Road, Andheri - East, Mumbai - 400 059 to 102, Hyde Park, Sakivihar Road, Andheri - East, Mumbai - 400 072 2011 -Bliss GVS Pharma Ltd recommended of 30% Dividend i.e. Rs. 0.30 per equity share 2012 -Company has acquired 70% management stake in the Company M/s. Kremoint Pharma Private Limited 2013 -Bliss GVS Pharma Ltd recommended a dividend of 40%. -Bliss GVS receives recognition for its Research & Development Lab from the Department of Scientific & Industrial Research (DSIR), Government of India. 2014 -Bliss GVS is named in Moneylife magazine's 'Wealth Creators 2004-2013' list, an annual study of companies that have created the maximum wealth for investors over the past 10 years. -Bliss GVS Wins - Outstanding Exports Award. 2015 -Bliss GVS Pharma wins Healthcare Services contract in Kenya 2016 -Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm.

1984 - Bliss GVS Pharma Limited was incorporated on 11th December, as public limited company and promoted by Mr Gautam Ashra. The company operates in two segments, health care products and pharma products. 2004 - Public shareholders of the company received an open offer by the Fedex Securities Ltd on behalf of Shri M G Wagle, Shri Gautam R Ashra & Shri Shibroor N Kamath. 2005 - Board of directors of the company had recommended the issue of bonus shares of 2 shares for every 5 shares. 2006 -Board of directors of the company on 9th May, 2006, had approved to takeover GVS Lab and to change the name of the company from 'Bliss Chemicals & Pharmaceuticals India Ltd' to 'Bliss GVS Pharma Ltd'. - Gautam Ashra, promoter director of the company, on 18th December 2006, sold 104,200 equity shares of the company for average sale price of Rs. 52.02 at the exchange. -Company has changed its name from Bliss Chemicals & Pharmaceuticals India Ltd. to Bliss GVS Pharma Ltd. 2007 - The board of the company had approved on 15th Jan 2007, to take over GVS Labs of S N Kamath for a consideration of Rs 160 million. The entire consideration will be paid by way of issue of 2,666,667 shares on a preferential basis to Kamath at a price of Rs 60 each (at a premium of Rs. 50 each). The takeover of GVS Lab was effective from Apr. 01, 2006. - The company had received an order of Rs. 25.00 crores for supply of Anti malarial Drugs for African Countries on November 2007. - The company set up its new manufacturing unit for tablets, dry syrup, oral suspension and suppository pessaries in the existing manufacturing facility at Palghar in Maharashtra. 2008 - Members at the extra ordinary general meeting of the company had approved split of shares of face Value of Rs 10 each into face value of Rs 1 each. -The company had fixed 18th March 2008 as the record date for the split of the equity shares of the company. The equity shares of face value Rs. 10 each will be sub divided in to face value of Rs. 1 each. -The Company has issued Bonus Shares in the Ratio of 3:5. 2009 -Company has received an Award from Pharmexcil -Company successfully completed its 25th year of operations. 2010 -Company has signed a Joint Venture Agreement with Kuwait -Mr. S N. Kamath, Promoter & Managing Director of the company has received a "National Award -2009 from Government of India in recognition outstanding performance Entrepreneurship under Medium Enterprises". -Registered Office of the Company has been shifted from 6/29-A, Udit Mittal Industry, Andheri Kurla Road, Andheri - East, Mumbai - 400 059 to 102, Hyde Park, Sakivihar Road, Andheri - East, Mumbai - 400 072 2011 -Bliss GVS Pharma Ltd recommended of 30% Dividend i.e. Rs. 0.30 per equity share 2012 -Company has acquired 70% management stake in the Company M/s. Kremoint Pharma Private Limited 2013 -Bliss GVS Pharma Ltd recommended a dividend of 40%. -Bliss GVS receives recognition for its Research & Development Lab from the Department of Scientific & Industrial Research (DSIR), Government of India. 2014 -Bliss GVS is named in Moneylife magazine's 'Wealth Creators 2004-2013' list, an annual study of companies that have created the maximum wealth for investors over the past 10 years. -Bliss GVS Wins - Outstanding Exports Award. 2015 -Bliss GVS Pharma wins Healthcare Services contract in Kenya 2016 -Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm.

Parent Organisation

Bliss GVS Pharma Ltd.

Founded

11/12/1984

Managing Director

Mr.Gagan Harsh Sharma

NSE Symbol

BLISSGVSEQ

FAQ

OPEN FREE* DEMAT ACCOUNT